Jaime E Hernandez

Summary

Affiliation: BioCryst Pharmaceuticals
Country: USA

Publications

  1. ncbi Impact of the 2009/2010 influenza A (H1N1) pandemic on trends in influenza hospitalization, diagnostic testing, and treatment
    Jaime E Hernandez
    BioCryst Pharmaceuticals, Durham, NC, USA
    Influenza Other Respi Viruses 6:305-8. 2012
  2. ncbi Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans
    George Atiee
    ICON Development Solutions, San Antonio, Texas, USA
    J Clin Pharmacol 52:1410-9. 2012
  3. ncbi Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States
    Jaime E Hernandez
    ID Clinical Development, Clinical Pharmacology, and Clinical Development, BioCryst Pharmaceuticals, Durham, NC, USA
    Clin Infect Dis 52:695-706. 2011

Collaborators

Detail Information

Publications3

  1. ncbi Impact of the 2009/2010 influenza A (H1N1) pandemic on trends in influenza hospitalization, diagnostic testing, and treatment
    Jaime E Hernandez
    BioCryst Pharmaceuticals, Durham, NC, USA
    Influenza Other Respi Viruses 6:305-8. 2012
    ..Approximately one-third remained untreated. Young children had the lowest rate of neuraminidase-inhibitor treatment during the 2009 pandemic (P < 0ยท05)...
  2. ncbi Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans
    George Atiee
    ICON Development Solutions, San Antonio, Texas, USA
    J Clin Pharmacol 52:1410-9. 2012
    ..The drugs were well tolerated. These results suggest no reason to expect an effect of concomitant administration of oseltamivir or rimantadine on the safety profile of peramivir in patients with influenza...
  3. ncbi Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States
    Jaime E Hernandez
    ID Clinical Development, Clinical Pharmacology, and Clinical Development, BioCryst Pharmaceuticals, Durham, NC, USA
    Clin Infect Dis 52:695-706. 2011
    ..We describe the clinical characteristics and outcomes of all patients for whom peramivir was requested under the eIND...